NOVOLIN N
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Jul 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
NOVOLIN N by Novo Nordisk is insulin, including novolin n is the regulation of glucose metabolism. Approved for glycemic control in adults. First approved in 1991.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLIN N is a human insulin (NPH) injectable formulation approved in 1991 for the treatment of diabetes mellitus. It is a basal insulin that provides intermediate-acting glycemic control, typically used in combination with rapid-acting insulins or oral agents. The drug works by facilitating glucose uptake in peripheral tissues and suppressing hepatic glucose production.
$0.053BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with $53M in annual Part D spending; brand teams are shifting to defensive positioning and cost optimization strategies.
Mechanism of Action
insulin, including NOVOLIN N is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Indications (1)
Clinical Trials (1)
Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects
Started Sep 2010
56 enrolled
Diabetes
Career Relevance
Working on NOVOLIN N positions pharma professionals in a defensive, cost-focused commercial environment where success is measured by slowing share erosion and maximizing margins before generic entry. Career trajectory is limited to lateral moves within managed decline roles; advancement typically requires transition to growth-stage products or strategic accounts.
Worked on NOVOLIN N at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.